Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers

Journal of Immunotherapy

Volumn 39, Issue 1, 2016, Pages 1-7

  Park, Tristen S ^a   Groh, Eric M ^a   Patel, Krishna ^a   Kerkar, Sid P ^a   Lee, Chyi Chia Richard ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

breast cancer; cancer testis antigen; MAGE A; melanoma; NY ESO 1; squamous cell cancer

Indexed keywords

CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN; MELANOMA ASSOCIATED ANTIGEN A; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; OVARY CANCER; PANCREAS CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CANCER; CANCER STAGING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS;

EID: 84951835243     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000101     Document Type: Article

References (37)

1. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011; 29: 550-557.
2. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4: 1-15.
3. Shantha Kumara HM, Grieco MJ, Caballero OL. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun. 2012; 12: 16-25.
4. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NYESO- 1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003; 3: 19-30.
5. Velazquez EF, Jungbluth AA, Yancovitz M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun. 2007; 7: 11-18.
6. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63: 6076-608383.
7. Akcakanat A, Kanda T, Koyama Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004; 54: 95-100.
8. Aung PP, Liu YC, Ballester LY, et al. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol. 2014; 45: 259-267.
9. Bergeron A, Picard V, LaRue H, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer. 2009; 125: 1365-1371.
10. Bujas T, Marusic Z, Peric Balja M, et al. MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma. Eur J Histochem. 2011; 55: 39-42.
11. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001; 92: 856-860.
12. Laban S, Atanackovic D, Luetkens T, et al. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 2014; 135: 1142-1152.
13. Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012; 25: 854-858.
14. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557.
15. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36: 133-151.
16. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015; 21: 1019-1027.
17. Sang M, Lian Y, Zhou X, et al. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011; 29: 8496-8500.
18. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917-924.
19. Vaughan HA, Svobodova S, Macgregor D, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 2004; 10: 8396-8404.
20. Bolli M, Schultz-Thater E, Zajac P, et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer. 2005; 115: 960-966.
21. Gibbs P, Hutchins AM, Dorian KT, et al. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res. 2000; 10: 259-264.
22. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 2011; 128: 2625-2634.
23. Chang HK, Park J, Kim W, et al. The expression of MAGE and GAGE genes in uterine cervical carcinoma of Korea by RT-PCR with common primers. Gynecol Oncol. 2005; 97: 342-347.
24. Lin J, Lin L, Thomas DG, et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGEA10 splice variants. Clin Cancer Res. 2004; 10: 5708-5716.
25. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res. 2004; 10: 6551-6558.
26. Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001; 85: 713-720.
27. Mengus C, Schultz-Thater E, Coulot J, et al. MAGE-A10 cancer/testis antigen is highly expressed in high-grade nonmuscle- invasive bladder carcinomas. Int J Cancer. 2013; 132: 2459-2463.
28. Kurashige T, Noguchi Y, Saika T, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001; 61: 4671-4674.
29. Yin B, Zeng Y, Wang X, et al. Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2014; 7: 4112-4119.
30. Xu X, Tang X, Lu M, et al. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer. Exp Mol Pathol. 2014; 97: 579-584.
31. Hou SY, Sang MX, Geng CZ, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res. 2014; 45: 44-51.
32. Otte M, Zafrakas M, Riethdorf L, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 2001; 61: 6682-6687.
33. Sugita Y, Wada H, Fujita S, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004; 64: 2199-2204.
34. Choi J, Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res. 2012; 32: 559-564.
35. Koketsu S, Watanabe T, Kazama S, et al. What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology. 2004; 51: 1648-1652.
36. Kubuschok B, Xie X, Jesnowski R, et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer. 2004; 109: 568-575.
37. Li M, Yuan YH, Han Y, et al. Expression profile of cancertestis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 2005; 11: 1809-1814.